Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren’t there better treatments for brain cancer?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about how a recent FDA rejection flies in the face of what had become conventional wisdom in the drug industry. Then we’ll talk about how the immunotherapy revolution in oncology has done little for glioblastoma, the cancer that killed Sen. John McCain. We’ll also dig into how a major trial on the cardiovascular benefits of fish oil could be a bad omen for Amarin and its efforts to turn a marginal product into a blockbuster. Finally, we’ll embark on a lightning round, covering the slow process of socialized medicine, the summer homes of sell-side analysts, and the future of digital medicine.